Zymeworks Financial Ratios
NASDAQ: ZYMEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
25.79+0.53 (+2.10%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zymeworks ratio analysis
Zymeworks earned a net margin of -76.6% in FY 2025, up from -160.8% a year earlier. Return on equity reached -30.2%, meaning Zymeworks generated -0.30 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Zymeworks financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | 4.14 | — | — |
| Price / sales | 18.94 | 14.92 | 9.41 | 1.24 | 31.67 | 61.13 |
| Price / book | 7.48 | 3.36 | 1.54 | 1.04 | 3.39 | 5.81 |
| Operating margin | -87.3% | -179.7% | -181.6% | 31.6% | -808.2% | -481.3% |
| Net margin | -76.6% | -160.8% | -156.1% | 30.1% | -794.0% | -463.5% |
| Free cash flow margin | -32.6% | -146.8% | -158.9% | 33.0% | -767.8% | -399.8% |
| Return on equity (ROE) | -30.2% | -36.2% | -25.5% | 25.2% | -85.0% | -44.0% |
| Return on assets (ROA) | -23.4% | -26.5% | -20.4% | 19.2% | -54.4% | — |
| Current ratio | 5.88 | 3.40 | 7.41 | 5.70 | 4.01 | — |
| Revenue growth | 38.9% | 0.4% | -81.6% | 1,446.0% | -31.5% | — |
| EPS growth | — | — | -190.5% | — | — | — |